Genisphere Closes $2 Million to Accelerate Development of Targeted Drug Delivery Platform

HATFIELD, Pa., Sep 16, 2014 (BUSINESS WIRE) -- Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has closed $2 million in private funding from existing investors, including Corporate Fuel Partners, a New York fund. This round of fundraising will accelerate Genisphere's targeted drug delivery initiative, following key milestones including the company's demonstration of cell-specific (cytosolic and nuclear) delivery of drugs with functional intracellular effects without apparent toxicity.

"3DNA nanotechnology is a versatile and unique delivery platform with potentially diverse and enormously important medical applications," noted Vladimir Muzykantov, MD, PhD, Director of the Center for Targeted Therapeutics and Translational Nanomedicine (CT3N) at the University of Pennsylvania.

"Genisphere has created an impressive portfolio of joint projects to identify the most promising leads and expand the evolving practical applications beyond the initial prototypes," he added. "Genisphere's corporate membership in CT3N offers it direct access to leading experts in the field; indeed, University of Pennsylvania counterparts have been intrigued by delivery opportunities provided by 3DNAtechnology."

Genisphere established these key collaborations to generate preclinical data showing the versatility and efficacy of the 3DNAplatform in targeted delivery of small drugs, biologics, and nucleic acids. Last year, Genisphere announced its first research collaboration agreement with MultiCell Technologies, Inc. (OTC: MCET), which is investigating the use of the 3DNA platform to help facilitate the targeted delivery of their lead drug candidate, MCT485, for the treatment of primary hepatocellular carcinoma. The number of collaborations has now grown to more than 25 and includes several projects with large pharmaceutical companies.

"Pre-clinical data have demonstrated specific targeting of tumors, selective killing of targeted cells, tumor shrinkage, and no observed toxicity," said Bob Getts, Genisphere's Chief Science Officer. According to Getts, key milestones achieved included excellent biodistribution profiles, transport across the blood-brain barrier, and specific accumulation in targeted tumors.

Getts also pointed out the flexibility of the 3DNA platform to deliver hundreds of tracking labels to targeted tissues, providing pharma companies with an option to incorporate a companion diagnostic into the drug development process. He summarized, "This round of funding will accelerate our joint efforts with our current collaborators, and gives Genisphere the resources to support additional partnerships."

Genisphere also plans to advance its own lead oncology compounds based on the 3DNA drug delivery platform.

About Genisphere

Genisphere LLC is a targeted drug delivery platform company. Genisphere's platform is a DNA-based nanotechnology called 3DNA®. 3DNA nanocarriers are used to deliver drugs in a highly targeted manner. Genisphere's technology is IP-protected and fully customizable to deliver a variety of therapeutics including small drugs, biologics, and nucleic acids. 3DNA nanostructures are composed entirely of DNA, engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic acid building blocks. Genisphere has been leveraging a collaborative model to advance its drug delivery platform, and continues to seek partnerships with biotechnology and pharmaceutical companies that could benefit from the company's platform technology. Genisphere is also advancing its own lead compounds based on the 3DNA platform. For more information, please visit http://genisphere.com

SOURCE: Genisphere LLC

Genisphere 
Bob Getts, 215-996-3027 
[email protected] 
or 
Chempetitive Group 
Ken Li, 312-997-2436 x 109 
[email protected]

Copyright Business Wire 2014

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.